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The spread of misfolded proteins may occur in many
neurodegenerative diseases. Mammalian prions
are currently the only misfolded proteins in which
high specific biological infectivity can be produced
in vitro. Using a system that generates infectious
prions de novo from purified recombinant PrP and
conversion cofactors palmitoyl-oleoyl-phosphatidyl-
glycerol (POPG) andRNA,weexaminedbydeuterium
exchange mass spectrometry (DXMS) the stepwise
protein conformational changes that occur during
prion formation. We found that initial incubation
with POPG causes major structural changes in PrP
involving all three a helices and one b strand, with
subsequent addition ofRNA rendering theN terminus
highly exposed. Final conversion into the infectious
PrPSc form was accompanied by globally decreased
solvent exposure, with persistence of the major
cofactor-induced conformational features. Thus, we
report that cofactor molecules appear to induce ma-
jor structural rearrangements during prion formation,
initiating a dynamic sequence of conformational
changes resulting in biologically active prions.
INTRODUCTION
The propagation of aberrant protein folding has emerged as a
potentially important mechanism for many neurodegenerative
diseases. Intracerebral inoculation of samples containing mis-
folded proteins can induce the formation and spread of neuro-
pathological features associated with these diseases throughout
the brain with varying degrees of efficiency (Castilla et al., 2005;
Clavaguera et al., 2013; Deleault et al., 2007; Legname et al.,
2004; Luk et al., 2012; Meyer-Luehmann et al., 2006; Sto¨hr
et al., 2012; Wang et al., 2010a). Of these diseases, spongiform
encephalopathies such as Creutzfeldt-Jakob disease and
bovine spongiform encephalopathy are the best characterized
for studying the phenomenon of transmissible protein misfoldingStructure 21, 2061–20(Prusiner, 1998), as well as the only ones in which proteins pos-
sessing significant levels of specific infectivity have been pro-
duced in vitro (Deleault et al., 2007, 2012b; Shikiya and Bartz,
2011). Spongiform encephalopathies are caused by prions,
which contain PrPSc, a misfolded conformer of the normal
cellular prion protein PrPC (Prusiner, 1998). The production of
high-titer infectious prions in vitro requires the addition of
nonprotein cofactor molecules such as RNA and phospholipids
(Deleault et al., 2007, 2012b). Misfolded PrP prepared in the
absence of cofactors is able to induce prion formation in vivo,
but possesses R105-fold less specific infectivity (Colby et al.,
2010; Deleault et al., 2012b; Kim et al., 2010; Legname et al.,
2004; Makarava et al., 2010, 2012). Cofactors maintain the
infectious conformation of PrPSc in purified recombinant prions
(Deleault et al., 2012b), although the mechanism of this is
unclear.
Preparations of PrPScmadewith purified recombinant PrP and
the cofactors palmitoyl-oleoyl-phosphatidylglycerol (POPG) and
RNA recapitulate the major features of prion disease, causing
transmissible spongiform encephalopathy in wild-type animals
with a rapid incubation time (Wang et al., 2010a). POPG, RNA,
and the protein misfolding cyclic amplification (PMCA) conver-
sion method are each necessary to form PrPSc and prion infec-
tivity in this system (Deleault et al., 2012a; Wang et al., 2010a).
Moreover, in this pathway, the sequential steps of cofactor addi-
tion result in stable insoluble intermediate species, enabling ex-
amination of the prion formation process in discrete steps. Taken
together, the chemically defined components, stable intermedi-
ates, de novo prion formation, transmission efficiency, and rapid
incubation time in this system provide a unique opportunity for
studying the formation of biologically active prions. Although it
is not known how closely the POPG and RNA cofactor pathway
resembles the process of prion formation in vivo, it provides a
tractable model in which the generation of bona fide prion infec-
tivity can be dissected at a structural level.
The atomic structure of PrPC contains three a helices, two
short b strands, and a flexibly disordered N terminus (Riek
et al., 1996, 1997). PrPSc contains significantly more b sheet con-
tent (Caughey et al., 1991; Moore et al., 2011) and is protease-
resistant (Bolton et al., 1982), but its insolubility (McKinley
et al., 1991) has hindered the standard structural techniques of
X-ray crystallography and solution nuclear magnetic resonance68, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 2061
Figure 1. Experimental Paradigm for Deuterium Exchange Mass Spectrometry Analysis of Prion Formation Process
(A) Schematic diagram of PrP conformations during in vitro formation of PrPSc, which is infectious to wild-type animals (Wang et al., 2010a).
(B) Coverage map of prion protein proteolytic peptides obtained by treatment of deuterium-exchanged and quenched samples with fungal protease XII and
pepsin. Unique high-quality peptides (including multiple charge states of the same peptide) were identified by LC-MS and are shown here as blue lines. Two hues
are used to visually distinguish adjacent peptides. Of 355 total peptides identified and shown here, an average of 160 were recovered in each experiment.
Numbers refer to mouse PrP amino acid sequence. Differences between nested peptides permitted fine resolution of deuterium exchange levels.
See also Figure S1 and Table S1.
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Structural Changes during Prion Formation(NMR). Hydrogen/deuterium exchange mass spectrometry
(DXMS) has proven to be a powerful method for studying protein
dynamics, domain structure, regional stability, and function
(Chalmers et al., 2011; Dai et al., 2008; Engen, 2009; Englander,
2006; Hamuro et al., 2003; Konermann et al., 2011; Zhang et al.,
2010). DXMS can reveal structural information about insoluble
proteins by measuring the solvent accessibility of peptide back-
bone amide hydrogens, reflective of the degree of steric blocking
and hydrogen-bonded secondary structure at each position.
Smirnovas et al. (2011) previously applied DXMS to the study
of native PrPSc lacking most posttranslational modifications,
finding a conformation with very low solvent access.
In this study, we apply the DXMS approach to the POPG
and RNA cofactor system for prion generation, in order to study
the dynamics of protein structural rearrangement during
prion formation. We report a stepwise progression of conforma-
tional changes during prion protein conversion into the
infectious form.
RESULTS
In order to assess protein conformational changes during PrPSc
formation, we examined the solvent accessibility of PrP at incre-
mental steps of the conversion process by which PrPSc is
formed using the cofactors POPG and RNA (Figure 1A). We2062 Structure 21, 2061–2068, November 5, 2013 ª2013 Elsevier Ltdtook advantage of specific properties of each PrP species that
allowed us to isolate them prior to performing deuterium ex-
change analysis of solvent accessibility (Figure S1A available
online). Anionic phospholipids, such as POPG, bind to PrP
and induce conformational change to an insoluble state (Wang
et al., 2007), which can be washed and separated from other
components of the initial mixture. We refer to this conformation
as PrP conversion intermediate 1 (PrPInt1). Following incubation
of PrPInt1 with RNA molecules, PrP remains insoluble (Fig-
ure S1B), in a form we refer to as PrP conversion intermediate
2 (PrPInt2). PrP-POPG-RNA complexes (PrPInt2) can be used
as a substrate for PMCA to form PrPSc that is infectious to
wild-type animals (Wang et al., 2010a). However, this PMCA re-
action does not convert 100% of the PrP molecules into PrPSc.
Therefore, to study PrPSc in isolation, we required a processing
step to eliminate unconverted PrPInt2. PrPSc is resistant to
limited proteolysis, with proteinase K treatment digesting only
the N terminus to residue 89 (Prusiner, 1998). In order to pre-
serve more of the N terminus of PrPSc, we used trypsin, an
endopeptidase which cleaves C-terminal to lysine and arginine
residues (Olsen et al., 2004). Following treatment with 5 ng/ml
trypsin, PrPInt2 is removed (Figure S1C). The same trypsin treat-
ment of the PMCA reaction product yields only the substrate
molecules that were converted into PrPSc. Most of these PrPSc
molecules are truncated to a protease-resistant core, whereas aAll rights reserved
Figure 2. Regional Solvent Accessibility of Prion Protein Conformations at Distinct Stages during PrPSc Formation
Prion protein conformations a-PrP (A), PrPInt1 (B), PrPInt2 (C), and PrPSc (D) were each purified and then incubated separately in deuterated water (D2O) for varying
time durations in order to assess regional solvent exposure. Deuterium incorporation was quenched, followed by proteolytic fragmentation of prion proteins and
liquid chromatography-mass spectrometry detection. Using centroid masses, deuterium incorporation for each peptide was determined relative to an
equilibrium-deuterated sample, from which deuteration values for PrP regions were computed. For each PrP conformer and incubation time, deuterium
incorporation is indicated by color, with areas of protein with low deuterium incorporation (highly protected) indicated in blue. Areaswith high deuterium exchange
(highly exposed) are indicated in red. The a helix and b strand secondary structural motifs from a-PrP NMR (Riek et al., 1996) are indicated below the solvent
accessibility map.
See also Figures S2–S4.
Structure
Structural Changes during Prion Formationsmall amount show the same electrophoretic mobility as full-
length PrP.
Generation of Overlapping Peptides from Prion Protein
To apply deuterium exchange to examine the conformational
changes in PrP during the prion formation process, we devel-
oped PrP fragmentation methods to enable resolution of solvent
protection differences to specific sequence locations. Previous
deuterium exchange studies of PrP have reported data from
28–44 peptic peptides, covering most of the C terminus with
minimal coverage of the N terminus (Lu et al., 2007; Nazabal
et al., 2009; Smirnovas et al., 2009; 2011). Through a series of ex-
periments, we identified conditions of reaction quenching and
extended digestion with fungal protease XIII and pepsin that
consistently yielded 160 high-quality peptides (Supplemental
Experimental Procedures; Table S1). This dense peptide
coverage created extensive overlap in most areas of the PrP
sequence (Figure 1B), enabling fine resolution of local deuterium
exchange differences, in some regions to the level of single
amino acid residues.Structure 21, 2061–20Deuterium Exchange of a-Helical Recombinant PrP
Using the optimized conditions for recovery of PrP-derived pep-
tides, we performed DXMS experiments on soluble recombinant
a-helical prion protein (a-PrP), which has the same structure as
native PrPC (Hornemann et al., 2004). Based on the insolubility
of the other analytes in this study and the previously reported
low solvent accessibility of native PrPSc lacking a glycosylphos-
phatidylinositol anchor and most glycans (GPI PrPSc) (Smirno-
vas et al., 2011), we focused this study on longer periods of
deuterium incubation, between 30 min and 24 hr. However, to
permit comparison with historical results, we also included a
shorter time point for a-PrP (Figure S2). Figure S3 shows the
mass spectra for a representative peptide, 99–110, to indicate
the effect of deuterium exposure on the isotopic envelope. We
found that the a-PrP N terminus is highly exposed, rapidly
showing full deuteration (Figure 2A). NMR spectroscopy has
determined that the structure of a-PrP has three a helices and
two small b strands (Riek et al., 1996). As expected, these motifs
showed protection from deuterium uptake, indicating lower sol-
vent exposure than other regions of PrP. b strand 1 (b1) wasmore68, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 2063
Figure 3. Changes in Prion Protein Solvent Accessibility during Each Step of PrPSc Formation
(A–C) Based on the deuterium exchange solvent accessibility data of each prion protein conformation, differences were calculated for each subsequent step in
PrPSc formation. Increases in deuterium incorporation (indicating increases in solvent accessibility) are depicted in shades of red. Decreases in deuterium
incorporation are depicted in shades of blue.
Structure
Structural Changes during Prion Formationexposed than b strand 2 (b2), possibly due to the deeper position
of b2 in the tertiary structure. These results are consistent with
previously reported deuterium exchange data for recombinant
a-PrP (Hosszu et al., 1999; Nazabal et al., 2009).
Deuterium Exchange of PrP Complexed to POPG
We next examined the conformation of PrP after incubation with
POPG (PrPInt1). As PrPInt1 is formed during PrP conversion into
PrPSc, it may be considered an intermediate in the process.
PrPInt1 is insoluble (Wang et al., 2007) but lacks the infectivity
of PrPSc (Wang et al., 2010a). Deuterium exchange of PrPInt1
shows an area of significant protection at 182–212 (Figure 2B).
The rest of the PrPInt1 structure is highly exposed, except for a
few short protected areas in the N terminus. When PrPInt1 is
compared to a-PrP, significant changes are evident (Figure 3A).
A few areas of the PrPInt1 N terminus, notably 34–38 and 50–55,
show less deuteration than the highly exposed a-PrP N terminus.
This is consistent with the formation of small a helices or b
strands. PrPInt1 deuterium exchange is reduced at 182–206, a
region that in a-PrP encompasses distal a helix 2 (a2), proximal
a helix 3 (a3), and the a2-a3 loop. This increased protection may
reflect an increase in packing of the endogenous a-helical struc-
ture or a secondary structural change, such as to b sheet. PrPInt1
also shows increased exchange at 143–167, suggesting the un-
folding of helix 1 (a1) and b strand 2 when POPG is added to PrP.
To visualize the three-dimensional locations of these regions, we
threaded the POPG-induced changes in deuterium uptake onto
the three-dimensional atomic structure of PrPC (Figure 4). It is
notable that the major areas of increased exposure (a1 and b2)
and decreased exposure (a2 and a3) are in physical proximity,
suggesting that the two changes may be related and occur as
part of a major structural rearrangement in PrP.
Deuterium Exchange of PrP following Incubation with
POPG and RNA
When PrP-POPG complexes (PrPInt1) are incubated with RNA,
the resulting protein species (termed PrPInt2) remains insoluble.
Deuterium exchange experiments indicate that PrPInt2 has a
conformation very similar to PrPInt1 (Figure 2C). Much of the
C terminus shows high solvent exposure, and the 183–212
region shows a significant degree of protection. The entire
N terminus shows a highly exposed structure, including expo-
sure of the small areas of N-terminal protection in PrPInt1
(Figure 3B).2064 Structure 21, 2061–2068, November 5, 2013 ª2013 Elsevier LtdDeuterium Exchange of PrPSc
Following conversion of PrPInt2 into PrPSc by seeded PMCA, we
isolated PrPSc molecules using trypsin digestion and then per-
formed deuterium exchange experiments (Figure 2D). As with
PrPInt1 and PrPInt2, the C-terminal region 182–212 is solvent pro-
tected, but to an even greater degree in PrPSc. For example,
peptide 196–201 shows high exposure in a-PrP, some protec-
tion in PrPInt1 and PrPInt2, and is further protected in PrPSc
(Figure S4). The rest of PrPSc also shows significant solvent pro-
tection, with dramatically reduced exchange compared to the
PrPInt2 predecessor (Figure 3C). This protection is particularly
notable in the hydrophobic domain (111–126) and in much of
the octapeptide repeat region, including 65–79.
DISCUSSION
Although the precise natural pathway of prion formation is not
known, PrP conversion in vitro using the cofactors POPG and
RNA has been shown to generate infectious prions that cause
spongiform encephalopathy in wild-type animals (Wang et al.,
2010a). Formation of prions in vitro in this manner provided us
the opportunity to examine the conformation of PrP during the
conversion process, by isolating intermediate forms of PrP that
occur after binding cofactor molecules but before conversion
into infectious PrPSc. In this study, we used deuterium exchange
mass spectrometry to identify the specific locations of PrP
conformational changes that occur during prion formation.
These data provide a dynamic map of specific folding events
that indicates that conversion cofactor molecules are respon-
sible for the major structural rearrangement that occurs during
prion formation.
Incubation with the phospholipid POPG caused a major struc-
tural rearrangement in PrP involving all three a helices and b
strand 2. Specifically, helix 1 and b strand 2 appear to unfold,
as they change from a rather protected to a highly exposed state.
In contrast, there is a significant decrease in solvent exposure in
the area surrounding the a2-a3 loop. This could be due to the
transformation of this region into a b sheet structure because
circular dichroism and Fourier transform infrared spectroscopy
experiments show that PrP binding to POPG is accompanied
by an increase in b sheet content (Kazlauskaite et al., 2003; San-
ghera and Pinheiro, 2002). The two aforementioned areas that
display the most significant change (i.e., increase or decrease)
in solvent exposure are adjacent in PrPC, suggesting that theirAll rights reserved
Figure 4. Atomic Structural Location of
POPG-Induced Prion Protein Conforma-
tional Changes
Changes in prion protein solvent accessibility
upon conversion from a-PrP to PrPInt1, depicted
by color shades, were threaded onto the
normal prion protein NMR structure using PyMOL.
The unstructured N terminus is shown as lines
for the sequence 23–117. The N terminus, C ter-
minus, and major structural features of a-PrP are
indicated.
Structure
Structural Changes during Prion Formationrearrangements may be related and occur as part of a broad
structural transformation in PrP upon interaction with POPG. In
addition to the C-terminal changes, POPG appears to induce
some areas of the PrP N terminus to form a structure with
increased protection, consistent with the formation of a new
secondary structure such as small a helices or b strands.
Furthermore, the increased protection seen at 111–117 may be
a result of POPG binding to the hydrophobic domain (Wang
et al., 2010b).
In contrast to the substantial conformational change that
occurs with POPG, the subsequent addition of the polyanion
RNA to PrPInt1 has a relatively small immediate effect on PrP
structure. Although the combination of POPG and RNA supports
PrPSc propagation (Wang et al., 2010a), POPG alone is not suffi-
cient (Deleault et al., 2012a), indicating an essential role for RNA
in this prion formation pathway. Given its meager immediate
structural effect on PrP, RNA may act subsequently during
PMCA to induce conversion to PrPSc. Nonetheless, addition of
RNA does have the immediate structural effect of increasing
the solvent exposure of the N terminus, possibly by destabilizing
secondary structural elements formed in the presence of POPG.
As such, the cumulative effect of POPG and RNA cofactors ren-
ders an exposed PrP structure from the N terminus to position
182. Interestingly, both the N-terminal (23–28) and central
(100–109) polybasic domains remain highly exposed following
incubation with POPG and RNA, consistent with evidence that
they bind PrPSc during templated conversion (Miller et al., 2011).
The conversion of PrPInt2 into PrPSc is accompanied by a
broad decrease in deuterium incorporation. This general in-
crease in solvent protection contrasts with the domain-specific
structural rearrangements in PrP that occurred with addition of
POPG. In the global closure of PrPSc structure, one notable
area of significant protection is the hydrophobic domain (111–
126), thought to be a critical region in PrPSc (Ho¨lscher et al.,Structure 21, 2061–2068, November 5, 2013 ª1998) for reasons that are not well under-
stood. It has been postulated that this re-
gion serves as a transition point during
PrPSc formation (Peretz et al., 1997).
During PrPSc formation, there is further
closure of the a2-a3 region, which first
showed increased protection in the pres-
ence of POPG. Indeed, based on statisti-
cal coupling analysis, the a2-a3 region
has also been hypothesized to initiate
transition to PrPSc (Chen and Thirumalai,
2013). Our findings indicate that thea2-a3 region (along with a1-b2) participates in the initial PrP
conformational change during cofactor incubation, whereas
the hydrophobic domain is not involved until subsequent PrPSc
formation.
Recently, Timmes et al. (2013) reported that serial PMCA
propagation in the presence of POPG and RNA could also sto-
chastically produce a noninfectious PrPSc conformer similar to
a self-propagating, noninfectious PrPSc conformer formed in
the absence of cofactors (Deleault et al., 2012b). Therefore, it
is important to note that for this study, we used a PrPSc sample
whose infectivity has been confirmed by bioassay in wild-type
mice. It is also worth considering the possibility that our prepara-
tions of PrPInt1 and PrPInt2 might be precursors of the noninfec-
tious rather than the infectious PrPSc conformer. However, the
data suggest that the intermediate preparations are on-pathway
to the infectious PrPSc conformer because most of the cofactor-
induced structural changes persist in the final, infectious PrPSc
product (Figure 2). Specifically, helix 1 of PrPC opens and helices
2 and 3 close upon cofactor introduction, and these relative ex-
change protection features are also present in PrPSc. The rela-
tively low yield of PrPSc from PrPInt2 suggests that the infectious
form may not be the only end point of the pathway, but PrPSc
indeed appears to come from the cofactor-induced intermediate
conformations.
Smirnovas et al. (2011) utilized the unique properties of GPI-
anchorless PrP expressed by transgenic mice to perform
DXMS. They found that GPIPrPScmolecules show very low sol-
vent accessibility in the sequence 83–223. Nearly all peptides in
this region from GPI PrPSc of prion strains 22L, Chandler, and
Me7 showed <40% deuterium incorporation after prolonged in-
cubation. Our results for OSU-strain PrPSc produced in vitro with
POPG and RNA cofactors also show a structure with low solvent
accessibility. However, with longer incubation (24 hr), some
areas of OSU POPG/RNA PrPSc show deuterium incorporation2013 Elsevier Ltd All rights reserved 2065
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Structural Changes during Prion Formationof >70%, though the C-terminal domain 182–212 and other re-
gions remain highly protected even with prolonged D2O incuba-
tion. Indeed, various approaches have shown that there exist
multiple PrPSc structures corresponding to distinct prion strains
(Bessen and Marsh, 1994; Smirnovas et al., 2011). The deute-
rium exchange differences between our PrPSc results and those
reported by Smirnovas et al. (2011) are likely related to prion
strain differences. Furthermore, whereas the pathway studied
here requires two different cofactors (POPG and RNA), a distinct
strain of infectious prions is produced via an alternative pathway
that uses only a single endogenous cofactor, phosphatidyletha-
nolamine (Deleault et al., 2012a). RNA depletion studies also
suggest the existence of different folding pathways employed
by different prion strains, which can be distinguished by their pol-
yanion requirement (Saa´ et al., 2012).
Forms of PrPSc have been reported that are sensitive to prote-
ase digestion (Colby et al., 2010; Kim et al., 2011; Pastrana et al.,
2006). The PrPSc findings we report here were obtained from
protease-resistant PrPSc, which has been more extensively
characterized as a conformer associated with infectious prions.
Furthermore, recent findings indicate that protease-sensitive
and protease-resistant PrPSc have similar structures (Sajnani
et al., 2012), suggesting that our results may reflect information
about the full population of PrPSc formed by this pathway.
Studies of secondary structure indicate that PrPSc has signif-
icantly more overall b sheet content than PrPC (Caughey et al.,
1998; Pan et al., 1993; Smirnovas et al., 2011). Two theoretical
structural models of PrPSc retain a helices 2 and 3 from PrPC
(DeMarco and Daggett, 2004; Govaerts et al., 2004). Our solvent
accessibility data for OSU PrPSc formed with POPG and RNA
cofactors show significant exposure changes in the region of
PrPC a helices 2 and 3, as does the data for GPI PrPSc (Smirno-
vas et al., 2011). This argues against PrPSc containing these
structures, although we cannot exclude the possibility that the
helices are retained but with greater packing or another cause
of increased solvent protection. Our results do indicate that the
PrPSc N terminus is protected.
By studying the step-by-step conformational changes in PrP
during prion formation, we have found that conversion cofactor
molecules drive structural rearrangements that initiate and
persist throughout the process of infectious PrPSc formation.
These results provide evidence that cofactors strongly influence
PrPSc structure, complementing previous observation of such
cofactor influence on PrPSc behavior (Deleault et al., 2012b).
Taken together, these findings illuminate an essential mecha-
nistic role for nonprotein cofactors in driving dynamic structural
changes during protein misfolding.EXPERIMENTAL PROCEDURES
Preparation of a-PrP
Mouse prion protein (MoPrP-A 23–230) was expressed in Escherichia coli and
purified as described previously, by nickel (Ni) affinity and ion exchange chro-
matography (IEC) (Wang et al., 2010a), or by nickel affinity, size exclusion chro-
matography, and high performance liquid chromatography (HPLC) (Makarava
and Baskakov, 2008). Recombinant a-PrP was used to represent PrPC, which
has the same structure, with the exception of mammalian posttranslational
modifications of glycosylation and GPI anchor on native PrPC. Initial peptide
recovery optimization experiments (using 1 or 4 mg PrP) used 0.5 mg/ml
HPLC a-PrP preparation in water. For subsequent peptide recovery optimiza-2066 Structure 21, 2061–2068, November 5, 2013 ª2013 Elsevier Ltdtion experiments, HPLC a-PrP was concentrated to 5 mg/ml by dialyzing
against absorbent resin in 10 mM acetate, 0.01 mM EDTA, pH 4.5 (Riek
et al., 1997). Following peptide recovery optimization, all deuterium exchange
experiments used a-PrP prepared by the Ni/IEC purification method.
Preparation of PrP-Cofactor Intermediate Species
Mixtures of prionprotein, POPG (Avanti Polar Lipids), andmouse liver total RNA
(extracted with Trizol, Invitrogen) were prepared as described (Wang et al.,
2010a). Briefly, POPG was incubated at 0.2 mg/ml with 0.25 mg/ml recombi-
nant a-PrP for 10 min at room temperature. This mixture was diluted 9-fold
into 0.25% Triton X-100, 150mMNaCl, 10mM tris pH 7.5, generating PrP con-
version intermediate 1 (PrPInt1). Following 5 min incubation, RNA was added to
0.15 mg/ml concentration, generating PrP conversion intermediate 2 (PrPInt2).
To prepare for deuterium exchange and remove excess phospholipid, each in-
termediate species was washed twice with 1% n-octyl-b-D-glucopyranoside
(nOG) (Anatrace Affymetrix), 150 mM NaCl, 8.3 mM Tris pH 7.2. Each wash
was performed by centrifugation at 100,000 3 g for 30 min at 4C, removal
of supernatant, and resuspension in wash buffer by vortexing for 10 s and son-
icating at 85% power (Misonix 4000 with Microplate Horn, Qsonica) for 1 min.
Preparation of PrPSc by Protein Misfolding Cyclic Amplification
The recombinant prion strain designated OSU was used in this study. OSU is
the recPrPSc sample originally produced de novo by F.W. as previously
described, and which is infectious to wild-type mice as determined by
bioassay (Wang et al., 2010a). Sufficient quantities of PrPSc for this study
were generated by propagating OSU PrPSc in the same manner using
PMCA. Mixtures of PrP, POPG, and mouse liver RNA were prepared as
described above. Each reaction mixture was then seeded with 10% volume
PMCA product OSU PrPSc, followed by incubation at 37C with intermittent
sonication (30 s per 30 min) at 75% power for 24 hr per round of PMCA.
The analytical methods are provided in Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.str.2013.08.025.
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